Piramal Pharma's US FDA inspection at Kentucky facility closed with VAI

The US FDA inspection at Piramal Pharma's Lexington, Kentucky manufacturing facility, previously disclosed on December 11, 2025, has concluded. The company received an Establishment Inspection Report (EIR) with a "Voluntary Action Indicated" (VAI) classification, marking the successful closure of the inspection. This intimation was filed on the first working day post-EIR receipt.